Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma

Exclusion Criteria

• •Patients previously treated with any anti-cancer therapy for HCC except for surgical resection and percutaneous ablative therapy
• •Patients treated with chemotherapy or other anti-cancer therapy (except surgical resection or percutaneous ablative treatment) in the previous 4 weeks
• •Patients with another primary tumor except basocellular carcinoma of the skin or in situ carcinoma of the cervix within the last 2 years
• •With a history of renal stone(s)
• •With a life expectancy \< 3 months
• •WHO performance status 3 or 4.
• •Patients with hypercalcemia (ionised serum calcium \> 1.35 mmol/l or albumin corrected serum calcium \> 2.68 mmol/l), previous/current calcium metabolic disease, taking calcium-lowering therapy or medication known to affect systemic calcium metabolism, or with marked laboratory abnormalities.
• •Patients with recurrent hepatocellular carcinoma, with known extrahepatic metastases, Okuda stage III disease and patients with a Child-Pugh score of C are also excluded.